Solvias and Enzymicals join forces in contract research, development and sustainable manufacturing.

Greifswald, Germany – November 24, 2021 - Enzymicals, one of the most experienced companies in Germany for in-vitro biosynthesis with biocatalytic process development and up-scaling expertise, today announced a non-exclusive partnership with Solvias (Kaiseraugst, Switzerland) opening access to alternative synthetic technology platforms for chemocatalysis and biocatalysis.

The ligands and specialty unit at Solvias has a proven track record for the efficient and successful development of catalytic processes while Enzymicals, a German enterprise focusing on industrial biocatalysis, has the perfect combination of complementary services with the aim of providing solutions to challenging chemical transformations.

Customers of both parties will benefit from proprietary catalyst portfolios and expertise for catalytic transformations with a suite of related custom synthesis and technology platforms. In additional, analytical testing solutions can be offered.
In the past decade both chemocatalysis and bio-catalysis have become strategic assets widely applicable to asymmetric reactions. Smart use of these processes can result in novel synthetic approaches in the area of process development with the common objective of achieving a more sustainable manufacturing.

CEO of Enzymicals AG, Dr. Ulf Menyes, said: “During our successful activities in industrial biocatalysis for diverse markets, we are constantly faced with the outstanding efficiency of chemocatalysis. The incorporation of the transformational power of Solvias ligands in our propositions now enables our customers to investigate a much wider range of solutions from the early beginning. In particular, the combination of both technologies within chemo-enzymatic cascades represents an innovative and currently very promising path for cost-efficient production strategies. I am really pleased that with Solvias we have a strong collaboration partner with complementary technology and expertise.”

Solvias’ Head of Ligands & Specialty Products, Dr. Jürgen Rotzler, said: “Overall, both, chemocatalysis and biocatalysis, are well-established technologies for large-scale production. The huge variety of commercially available ligands and the opportunity to tailor enzymes to specific needs by evolution provides chemists with complementary technologies to tackle everyday challenges in organic chemistry. We are very happy to be now able to add a further component to our scientist’s tool box by collaborating with Enzymicals and therefore to support our customers to a greater extend in bringing better and safer products to the market faster.”

Enzymicals AG
Walther-Rathenau-Straße 49a
17489 Greifswald
GERMANY

About Enzymicals AG

Enzymicals stands for tailor made enzymes, customized chemicals and individual process solutions.
Since its founding in 2009, the German enterprise Enzymicals AG has created a customer-oriented industrial platform for process development and piloting of chemo-biocatalytic synthetic routes for high-quality fine chemicals.
The company built a bridge between academic research to industrial application and focuses on the three business segments: Enzymes (production of biocatalysts), Chemicals (production of fine and special chemicals) and Solutions (customer-specific solutions to questions of chemo-biocatalytic synthesis, process development and piloting). This orientation is based on profound expertise in industrial biocatalysis and development of competitive enzymes for organic synthesis. Together with its network partners, the service can be expanded to cGMP production and bulk scale supply.

For more information, please visit https://www.enzymicals.com

About Solvias AG

Solvias is an established worldwide leader in contract research, development and manufacturing with headquarters in Kaiseraugst near Basel, Switzerland. Our highly qualified employees deliver unrivaled expertise, service and value to customers in the pharmaceutical, biotech, material science and cosmetic industries.
Our laboratories operate to the highest standards and in accordance with ISO, GMP, GLP and FDA regulations. Drawing on a proven 20-year track record of scientific excellence, we provide integrated services to develop, analyze and test a wide range of chemical substances and biopharmaceuticals, enabling our customers to bring safer and better products to the market faster.
Solvias owns the most divers library of ligands for chemocatalysis, produces and commercializes a wide variety of chiral phosphine ligands and catalysts for use in catalytic asymmetric hydrogenation and many other asymmetric catalytic reactions. Several of these ligands / catalysts are used in industrial production processes.

For more information, please visit https://www.solvias.com

This release was published on openPR.